CAR-T Cell Therapies – China In-Depth – China In-Depth: CAR T-Cell Therapy (China)
CAR T-cell therapy is a novel approach to cancer adoptive immunotherapy. The ongoing regulatory reforms, such as the breakthrough therapy designation (BTD) and priority review pathway, have inspired both domestic and foreign firms to develop advanced CAR T-cell treatments to enhance the therapeutic options available for the treatment of relapsed/refractory patients. Several CAR T-cell therapies—such as ciltacabtagene autoleucel (Nanjing Legend Biotech’s Cilta-cel), tisagenlecleucel (Novartis’s Kymriah), zevorcabtagene autoleucel (Carsgen Therapeutics’ Zevor-cel)—are expected to launch over the next ten years, establishing China as the new force in the CAR T-cell therapy field. In this report, we present a comprehensive overview of current and emerging CAR T-cell therapies, pricing and market access, physicians’ views, and future opportunities for this paradigm-shifting treatment approach.
QUESTIONS ANSWERED
- What are the notable developments in the pipeline? Who are the key players, and what novel targets are they exploring?
- Which will be the most commercially relevant drugs in China’s CAR T-cell therapy market and why?
- What are the market access considerations for emerging CAR T-cell therapies in China?
- What challenges remain and could limit widespread and maximum adoption of CAR T-cell therapies in China? What are the future directions and opportunities?
PRODUCT DESCRIPTION
China In-Depth offers comprehensive market intelligence, includingworld-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
RELEASE DATE
December 2023
GEOGRAPHY
China
PRIMARY RESEARCH
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 75 hematologist-oncologists.
FORECAST
10-year, annualized, drug-level sales of key CAR T-cell therapies through 2032, based on primary and secondary market research to formulate bottom-up assumptions.
EMERGING THERAPIES
Phase III/PR: 3 drugs; Phase II: 20+ drugs; coverage of select preclinical and Phase I products.
Sahil Arora, M.B.A., Healthcare Research & Data Analyst, China In-Depth. Prior to joining Clarivate, Mr. Arora was a senior associate on the Intelligence and Insights team at Prescient Healthcare Group. He has several years of experience in competitive intelligence, key opinion leader (KOL) identification, KOL profiling, and social media footprint analysis. He holds a master’s degree in pharmaceutical management from NIPER Mohali in India.